CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 93 enrolled
Drug / intervention
Molecular biology analysis of pancreatic intra-cyst fluidgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03305146
NCT03305146N/AActive

Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors.

Hospital St. Joseph, Marseille, France·interventional·Posted Oct 9, 2017·Updated Apr 14, 2022

In Brief

A clinical study evaluating Molecular biology analysis of pancreatic intra-cyst fluid for Pancreatic Cyst and 4 related conditions. Active but no longer recruiting, targeting 93 participants across 11 sites.

Detailed Summary

The main objective of the study is to compare the diagnostic accuracy of intra-cystic fluid DNA molecular analysis to standard diagnostics. The secondary objective of the study is to evaluate the feasibility of intra-cystic fluid DNA molecular analysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance

Timeline

N/AActive
20172018201920202021202220232024202520262027
First PostedOct 9, 2017
Enrollment StartJan 1, 2017
Primary CompletionDec 1, 2017
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.7 years ago

Interventions

Molecular biology analysis of pancreatic intra-cyst fluidgenetic

The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations. For molecular biology technique, the samples will be processed within the UMR\_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen). The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA.